SCHEMBL20675615

SCHEMBL20675615

Cc1cn(C(=O)OCc2ccccc2)nc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.47
SMN1; SMN2 Q16637 6/20 0.46
RAB9A P51151 6/20 0.45
NPC1 O15118 5/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
HTR2C P28335 1/20 0.45
P2RX4 Q99571 2/20 0.44
CYP2C19 P33261 1/20 0.44
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
P2RX1 P51575 1/20 0.43
P2RX3 P56373 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
MAPK1 P28482 2/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42
MAPT P10636 1/20 0.42
CTRB1 P17538 1/20 0.42
ALKBH1 Q13686 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20471120 0.86 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL21672941 0.83 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL31721520 0.82 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL20181866 0.78 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL31721482 0.78 HTR2C (0.42) ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL20181863 0.77 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL16804931 0.77 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL19936531 0.76 DHODH (0.45) ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL29010237 0.74 NPC1 (0.43) ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1
SCHEMBL25753535 0.73 MAPT (0.49) ALDH1A1SMN1; SMN2RAB9ANPC1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220220111-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF NUVATION BIO OPERATING COMPANY INC (US) 2022-07-14 US disclosed
US-10793561-B2 1,8-naphthyridinone compounds and uses thereof NUVATION BIO INC. (US) 2020-10-06 US disclosed
US-20190023702-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) 2019-01-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220220111-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF NME1, ADORA2A, GPR68 ALDH1A1 1543/4885SMN1; SMN2 3645/4885RAB9A 1317/4885
US-10793561-B2 1,8-naphthyridinone compounds and uses thereof NME1, ADORA2A, GPR68 ALDH1A1 1543/4885SMN1; SMN2 3645/4885RAB9A 1317/4885
US-20190023702-A1 1,8-NAPHTHYRIDINONE COMPOUNDS AND USES THEREOF NME1, ADORA2A, GPR68 ALDH1A1 1543/4885SMN1; SMN2 3645/4885RAB9A 1317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.